Part 4


Presentation of breast cancer

Breast lump 

****** discharge and / or inversion 

Eythema, peau d'orange, ****** ulcer / eczma 

Skin dimpling / deforrmity / puckering 

Axillary mass 


1 of 41

Diagnostic score for breast cancer

Physical exam = P/E 

Mammography = M 

US = U 

Cytology = C 

Core biopsies = B 

1 = normal 

2 = benign 

3 = intermediate 

4 = suspicious of malignancy 

5 = malignancy 

2 of 41

Classic lobular carcinoma in situ (LCIS) / lobular

Not considered breast cancer 

But a marker of increased risk 


3 of 41

Ductal carcinoma in situ (DCIS), pleomorphic LCIS

Considered a cancer 

Remain in the basement membrane of the tubules of the breast 

4 of 41


Drug given to a patient who is oestrogen receptor positive 

Reduces risk of recurrence so can be continued after remission 

5 of 41

1 and 2 = early, 3 = locally advanced

Stage 1 and 2 breast cancer = 

Stage 3 = 

6 of 41

Inflammatory breast cancer

A form of locally advanced breast cancer 

Most aggressive form 

Presents as swelling, tenderness and redness 

Sentinel lymph node biopsy is contraindicated 

7 of 41

Herceptin (trastuzumab)

Treatment for HER-2 receptor (EGFR) +ve breast cancer 

8 of 41


Breast cancer = 80-90% 

High risk of sarcoma 

High risk of childhood leukaemia 

Adrenal cancer 

9 of 41

Lung Cancer

Clinical features 

Most common:

Anorexia and weight loss 

Cough, dyspnea 

Supraclavicular LNs 


Chest pain, haemoptysis 

Hoarseness, dysphagia 

Bone pain, clubbing 

Neurological manifestations 

10 of 41

Small cell lung carcinoma

10-15% of lung cancers 

Predominantly smokers 

More aggressive form 

Rarely resectable (<1%) therefore surgery is ineffectibe 

Chemosensitive but prone to recurrence and resistance to chemotherapy 

11 of 41


80-85% of lung cancers 


Squamous cell carcinoma 

Large cell 

12 of 41


Most common type of cancer in NSCLC 

Due to EGFR mutations 


and more 

13 of 41

5, 8 and 9

What numbered lymph nodes are missed in endobronchial USS 

14 of 41

Indications for surgery

Stage I and II (some with IIIa)

Adequate lung function (FEV1 >60% - should allow pneumonectomy) 

No significant co-morbidities 

15 of 41

Chemotherapy in NSCLC

Chemotherapy in what cancer? 

Platinum + new agents (gemcitabine) 

Chemoradiotherapy in N2/N3 disease + immune therapy 

16 of 41


Overexpressed in 60% of NSCLC 

Inhibition especially effective in adenocarcinomas 

Response correlates with mutation in the gene 

Resistance common 

Most mutations are exon-19 short in frame deletions, or exon-21 point mutations 

17 of 41

Ab that blocks PD-1


18 of 41

Stage IV squamous cell LC

Treat with:


Platinum chemo 


19 of 41

Stage IV non-squamous cell LC without mutations

Treat with:

Platinum chemo 


20 of 41

Non-SCC with EGFR or ALK rearranged

Treat with 

Tyrosine kinase inhibitors (for EGFR)

Platinum chemo 


21 of 41



Both sides of chest expanding - Yes

Breath sounds same on both sides - Yes 

Lung resonant on both sides - Yes 

Wheezes from narrow airways - Yes 

22 of 41

Severe asthma attack

Breathless at rest, speech in words or phrases 

RR >25 

Pulse >110

Loud wheeze 

<33% predicted PERF/FEV1

PaCO2 >40mmHg

PaO2 < 60mmHg 

23 of 41

Life threatening asthma attack

Cyanosed at rest, too breathless to speak 

RR > 25 

Pulse >110 or may be bradycardic 

May have a quiet chest 

<20% predicted PERF/FEV1

PaCO2 >45mmHg 

PaO2 <60mmHg despite O2 therapy 

24 of 41

Types of hypersensitivity

Type 1 = Allergy 

Mediated by IgE mast cells 

Type 2 = Antibody mediated - complement mediated 

Triggered by complexes of Ab-Ag (IgM,IgG) against cell surface / ECM 

Type 3 = Immune complex mediated 

Soluble immune complexes, IgM and IgG 

Type 4 = Cell mediated 

25 of 41

Serum sickness

Accumulation of Type III mediated immune complexes in the body 

26 of 41


A combination of type 1 and type 4 hypersensitivity 

27 of 41




Chest tightness 


28 of 41

Allergic asthma

Easily recognised

usually commences in childhood 

associated with past Fhx of allergic disease

Eosinophillic inflammation

Good response to ICS

29 of 41

Non-allergic asthma

Sputum may be neutrophilic 

Eosinophilic or with few inflamm cells 

Less response to ICS 

30 of 41

Late onset asthma

More common in women

Tendency to be non-allergic

 Higher doses of ICS required 

31 of 41

Asthma with fixed airflow limitation


Airflow limitation due to airway remodelling 

32 of 41



33 of 41





34 of 41

Short acting anticholinergic/musc antagonist


35 of 41

Long acting antiC/M antagonists



36 of 41

Histamine and Leukotriens

Bronchoconstrictor mediators from Mast cells 

37 of 41


10% increase when combined with SABA 

Attenuates IL-13 goblet induced metaplasia 

(IL-13 most important cytokine in hypersecretion) 

38 of 41


Group of drugs that:

Suppress the Th2 airway inflammation

Reducing infiltration and activating of eosinophils 

as well as other cells 

39 of 41

Long acting ICS

Fluticasone Furoate 

40 of 41

FF / Vilanterol

Only licensed ICS/LABA in asthma 

41 of 41


No comments have yet been made

Similar Medicine resources:

See all Medicine resources »See all Medicine resources »